Results 101 to 110 of about 422,851 (117)

Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial

Ophthalmology and Therapy, 2023
Mengli Zhu, Jilong Hao, Ke Fan
exaly  

Top bar navigation

Frontiers in Immunology, 2023
Zhiyu Huang, Fajun Xie, Xiangrui Meng
exaly  

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk

Acta Pharmacologica Sinica, 2022
Zhenlin Zhang, Ru-Chun Dai, Cheng-Qing Yi   +2 more
exaly  

A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects

Cancer Chemotherapy and Pharmacology, 2020
Guo-Ping Yang, Can Guo
exaly  

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

BioDrugs, 2023
Huiping Li, Helong Zhang, Minghong Bi
exaly  

People also looked at

Frontiers in Pharmacology, 2020
Hong Zhang, Quan Liu, Wei Wei
exaly  

UBE2QL1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene

Human Mutation, 2013
Noel Clarke, Anne-Bine Skytte, Eamonn R Maher   +2 more
exaly  

Analysis and Prediction of QL14h by Database Application

Wireless Personal Communications, 2018
Baijuan Wang, Qingyan Tang
exaly  

Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration

Ophthalmology Retina
Miroslav Veith, Ignasi Jürgens, Agnieszka Nowosielska   +2 more
exaly  

The ubiquitin‐conjugating enzyme UBE2QL1 coordinates lysophagy in response to endolysosomal damage

EMBO Reports, 2019
Marja Jäättelä, Bin Liu, Chrisovalantis Papadopoulos   +2 more
exaly